Aethlon Medical Inc. Advances Hemopurifier Clinical Trial Following Positive Safety Review, Opens Enrollment for Next Patient Cohort
Reuters
Jul 15, 2025
<a href="https://laohu8.com/S/AEMD">Aethlon Medical Inc</a>. Advances Hemopurifier Clinical Trial Following Positive Safety Review, Opens Enrollment for Next Patient Cohort
Aethlon Medical, Inc. has announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial, AEMD-2022-06, has completed a scheduled safety review. The board has recommended advancing to the next patient cohort without any modifications. This trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab," is assessing the Hemopurifier's safety, feasibility, and optimal dosing. The primary endpoint is the incidence of adverse events and clinically significant changes in safety laboratory tests. Aethlon Medical aims to use the findings to inform the design of a future efficacy and safety study required for regulatory approval. Enrollment for Cohort 2 is now open, with participants set to receive two Hemopurifier treatments over a one-week period at three clinical sites in Australia. The trial intends to enroll approximately 9 to 18 patients. Results from this study will be presented in the future as the trial progresses.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA29155) on July 15, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.